Monthly archive | PharmaTutor

11 August 2016

Research Associate Require @ Pfizer

All over the world, Pfizer colleagues work together to positively impact health for everyone, everywhere. Our colleagues have the opportunity to grow and develop a career that offers both individual and company success; be part of an ownership culture that values diversity and where all colleagues are energized and engaged; and the ability to impact the health and lives of millions of people. Pfizer, a global leader in the biopharmaceutical industry, is continuously seeking top talent who are inspired by our purpose to innovate to bring therapies to patients that significantly improve their lives.

Post : Research Associate

11 August 2016

Faculty requirement in Sultan Ul Uloom College of Pharmacy

Sultan Ul Uloom College of Pharmacy was established in the year 1997, approved by AICTE, Pharmacy Council of India and Affiliated to Jawaharlal Nehru Technological University Hyderabad. The college has successfully completed 18 years of existence with excellent results year after year. The college has special distinction of producing 8 University Gold Medalists. The faculty and non- teaching associates have demonstrated teamwork in carrying innovations to upgrade the standard of quality improvement in the areas of Pharmacy education.

Post : Faculty

11 August 2016

Vacancies in Olive Healthcare | Opening in QA, QC, Production, Regulatory Affairs, Warehouse, Engineering - WALK IN INTERVIEW

The Olive Group of companies ventured into the world of soft gelatin formulations by setting up its first manufacturing facility over 3 decades ago. Over the years with the advancement and innovation of soft gelatin related technology, and the ever increasing emphasis on cGMP standards, we have set up two state of the art manufacturing units in India.

We are looking for well qualified .experienced and dynamic! personnel for following positions in our USFDA / EU GMP approved | manufacturing facility at Daman;

Post: Manager QA, Executive QC, Production Manager, Warehouse, Engineer

Read more about Lilly gets DMC recommendation to continue MONARCH 2 phase 3 trial of abemaciclib without modification

Eli Lilly and Company announced that following a pre-planned interim analysis for MONARCH 2, an independent Data Monitoring Committee (DMC) provided the recommendation to continue the study without modification as the interim efficacy criteria were not met. The MONARCH 2, phase 3 trial compares abemaciclib plus fulvestrant versus placebo with fulvestrant in women with hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) locally advanced or metastatic breast cancer.

Read more about Proteostasis Therapeutics complete preclinical milestone in Astellas collaboration

Proteostasis Therapeutics, Inc., a clinical stage biopharmaceutical company developing small molecule therapeutics to treat diseases caused by dysfunctional protein processing, announced that it has successfully completed a key preclinical milestone in its collaboration with Astellas Pharma Inc. (Astellas). The milestone, which triggered an undisclosed payment from Astellas, demonstrated that selective modulation of the Unfolded Protein Response (UPR) pathway in vitro is potentially an effective disease-modifying approach in the treatment of multiple diseases with few or no therapies currently available.

Read more about Shire launch Vonvendi, a recombinant treatment for adults affected by VWD in US market

Shire plc, a leading global biotechnology company, announced the US launch of Vonvendi [von Willebrand factor (Recombinant)], the only recombinant treatment for adults living with von Willebrand disease (VWD).

Read more about U.S. FDA Approve Heron Therapeutic’s SUSTOL Extended-Release Injection

Heron Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved SUSTOL® (granisetron) extended-release injection. SUSTOL is a serotonin-3 (5-HT3) receptor antagonist indicated in combination with other antiemetics in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens.

11 August 2016

DRUGS AND INTELLECTUAL PROPERTY RIGHTS: POSITIVE AND NEGATIVE ASPECTS

{ DOWNLOAD AS PDF }

ABOUT AUTHORS
J A Sathwara¹, A M Bhandari²
¹* Department of Pharmacology, A.R.College of Pharmacy & G.H.Patel Institute of Pharmacy, Anand ,Gujarat
² Department of Clinical Pharmacy, A.R.College of Pharmacy & G.H.Patel Institute of Pharmacy, Anand ,Gujarat
*jignasa.sathwara@gmail.com

ABSTRACT
The development of drugs is costly for the Pharmaceutical companies and without the protection of Intellectual Properties, the formula for the drug can easily be duplicated and can be synthesized at cheaper cost. The U.S. intellectual property laws protect the rights of small inventors and large corporations alike to guarantee “the first to invent” the exclusive right to the patents. To solve the drug price inflation within the U.S., an initiative has been taken that drug patents are different from other innovations. Under the new plan, new drugs would be sold at generic prices upon FDA’s approval. New drugs will no longer be rewarded by net-profit from sales, but instead by Medical Innovation Prize Fund at a level of 0.5% of the gross domestic product, that provide money to developers of new products based upon the actual impact on health outcomes over ten years. Although patents protect the rights of the investors and courage innovations, there are certain ideas that should not been patented. Potentially lifesaving technologies should be separated from other type of innovations, and money making should not be the only inceptive for drug discovery. The number of worldwide who have access to medicines is low, an allowing patents on drugs, although increase the number of advancements in lifesaving technologies; it will decrease the number of people who access to them. International efforts should focus on allocating monetary motivation to provide people to access drugs.

Read more about US FDA issues updated recommendations on submitting new 510(k) for medical device modifications

The US Food and Drug Administration (FDA) issued draft updated recommendations to help manufacturers determine when they are required to notify the FDA about modifications made to certain medical devices already on the market, including a separate guidance applicable to software devices.

Read more about Coherus Biosciences Submits 351(K) BLA To U.S.FDA For CHS-1701

Coherus BioSciences, Inc. announced submission of the biologics license application (BLA) for CHS-1701, a pegfilgrastim (Neulasta®) biosimilar candidate, to U.S. FDA under the 351(k) pathway.

Search

August 2016

Research Associate Require @ Pfizer

RECOMMENDED POSTS

Subscribe with us

Jobs by Category